Oncology

Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, discusses her study on how social determinants of health impact the health perceptions of Black and Hispanic ovarian cancer survivors, highlighting significant health disparities.

Although the amount of real-world evidence demonstrating the safety and efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma (HCC) has been growing, data on liver function evolution as a prognostic factor for overall survival are lacking.

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma.

Cigarette smoking among other modifiable risk factors were significantly associated with cancer cases and deaths.

A long-awaited report from the Federal Trade Commission (FTC) finds that vertical integration and consolidation have worked against consumers and independent pharmacies.

To conclude our interview with him, Ravin Ratan, MD, MEd, of MD Anderson, explains the importance of caring for all patients and why he tries to own the process of patients feeling confident that they received the attention they deserve.

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC).

Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, breaks down the causes of the ongoing cancer drug shortage, as well as its impact on clinical trials.

e-Cigarette users may be less likely to undergo lung cancer screening, study reveals.

Dedifferentiated liposarcoma is a fast-growing and more aggressive type of soft tissue sarcoma that originates as a well-differentiated sarcoma and has a typical diagnosis age of 40 to 60 years.

In part 3 of our interview, Jessica K. Paulus, ScD, Ontada, addresses the importance of understanding data sources and their impact on clinical research.

Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.

A study finds limited changes in hospice utilization, highlighting challenges in real-world implementation.

The National Comprehensive Cancer Network (NCCN) survey finds 89% of centers continue to report shortages for at least one type of systemic therapy.

Early findings from a new preclinical study indicate that dual blockade of aurora-A kinase and PD-L1 signaling can inhibit tumor growth in triple-negative breast cancer (TNBC), treatment for which has historically remained limited.

“The screening victory there is going to take some more time to show its benefit at the population level,” notes Jessica K. Paulus, ScD. “Some of these things are just going to be reductions in mortality that we have to wait to observe over time.”

The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.

In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas.

Investigators from Germany conducted a systematic review of different MRI features in soft tissue sarcoma (STS) that are used to infer tumor histological grade.

Neurotrophic tyrosine receptor kinase (NTRK)–positive locally advanced or metastatic solid tumors can now be treated with the first FDA-approved treatment option.

Nivolumab/cabozantinib combination therapy showed consistent benefits across various subgroups in patients with advanced renal cell carcinoma (RCC).

Judge rules Florida's ban on gender-affirming care for minors unconstitutional; first consensus definition for long COVID aims to standardize diagnosis and care; pilot program for clinical trial diversity discontinued due to high cost and lack of impact.

Posters presented at ASCO 2024 found positive responses in the prediction of tumor types and prognostic outcomes in patients with advanced solid tumors and HR+/HER2-negative (HER2–) metastatic breast cancer.